The effect of the da Vinci Vessel Sealer on robot-assisted laparoscopic prostatectomy complications.

Journal: Journal of robotic surgery
Published Date:

Abstract

The da Vinci Vessel Sealer is a major contributor to the total cost of robot-assisted laparoscopic prostatectomy (RALP). We aimed to assess whether the use of the Vessel Sealer is associated with better surgical outcomes in a population of patients that underwent RALP with lymphadenectomy. We tested whether the use of the Vessel Sealer is associated with the development of lymphocele and/or other surgical outcomes. Most surgeons used the Vessel Sealer in almost all or almost no patients. Thus, to avoid the potential confounding variable of surgeon skill, we performed the initial analyses using data from a single surgeon who changed practice over time, and then using the entire population. Overall, the Vessel Sealer was used in 500 (36%) RALPs. Surgeon 1 performed 492 surgeries, and used the Vessel Sealer in 191 (39%). The Vessel Sealer was not associated with better surgical outcomes in patients operated on by Surgeon 1. The odds ratio for development of lymphocele was 1.95 (95% confidence interval [CI] 0.57-6.75). In the entire population, use of the sealer was significantly associated with a very small reduction of blood loss (22 cc, CI 13-30) but with a 32-min increase in the operating room time (CI 26-37). Use of the Vessel Sealer will have, at best, a very small effect on RALP outcomes that is of highly questionable relevance given its cost. In light of these results, the Vessel Sealer will only be used at our institution in the context of clinical trials.

Authors

  • Francesco Pellegrino
    Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy.
  • Amy L Tin
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Daniel D Sjoberg
  • Nicole E Benfante
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ryan C Weber
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Shaun P Porwal
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Alberto Briganti
    Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy.
  • Francesco Montorsi
    Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, URI, IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132, Milan, Italy.
  • James A Eastham
    Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Vincent P Laudone
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Andrew J Vickers
    Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.